SLC5A2 and atrial fibrillation: In a meta-analysis including 6 randomised controlled trials and 9467 patients with HFrEF, Sfairopoulos et al. [98], demonstrated a significant reduction in the risk of AF (RR 0.62, p = 0.005) and AF/AFL (RR 0.64, p = 0.004) in the SGLT2 group compared to the placebo group.